Omada Health (NASDAQ:OMDA - Get Free Report) had its price target reduced by investment analysts at JPMorgan Chase & Co. from $30.00 to $25.00 in a report released on Monday, Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 78.48% from the company's previous close.
A number of other research analysts have also recently weighed in on the company. Weiss Ratings upgraded Omada Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, November 9th. Zacks Research cut shares of Omada Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 4th. Wells Fargo & Company cut their target price on shares of Omada Health from $22.00 to $19.00 and set an "equal weight" rating on the stock in a report on Friday, November 6th. Citizens Jmp boosted their price objective on Omada Health from $27.00 to $32.00 and gave the company a "market outperform" rating in a research report on Friday, August 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Omada Health in a research report on Friday, September 11th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $25.92.
Get Our Latest Stock Report on Omada Health
Omada Health Trading Down 2.3%
Shares of Omada Health stock traded down $0.32 during trading hours on Monday, hitting $14.01. 646,792 shares of the company were exchanged, compared to its average volume of 1,272,537. The stock has a market capitalization of $868.97 million, a price-to-earnings ratio of 66.60 and a beta of 2.13. Omada Health has a 1 year low of $10.28 and a 1 year high of $25.45. The business has a 50-day moving average of $19.30 and a 200-day moving average of $17.71.
Omada Health (NASDAQ:OMDA - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. The firm had revenue of $91.31 million during the quarter. Omada Health had a net margin of 4.21% and a return on equity of 5.71%. As a group, research analysts anticipate that Omada Health will post 0.09 earnings per share for the current fiscal year.
Insider Activity
In other Omada Health news, CFO Steven L. Cook sold 6,800 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.86, for a total value of $148,648.00. Following the transaction, the chief financial officer directly owned 173,906 shares in the company, valued at approximately $3,801,585.16. This trade represents a 3.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sean P. Duffy sold 12,944 shares of the firm's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $19.22, for a total value of $248,783.68. Following the transaction, the chief executive officer owned 382,594 shares in the company, valued at approximately $7,353,456.68. This trade represents a 3.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 79,322 shares of company stock worth $1,720,914. Company insiders own 6.38% of the company's stock.
Hedge Funds Weigh In On Omada Health
Large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Omada Health during the 2nd quarter worth $48,775,000. Marshall Wace LLP boosted its stake in shares of Omada Health by 790.1% in the 3rd quarter. Marshall Wace LLP now owns 920,258 shares of the company's stock valued at $19,151,000 after purchasing an additional 816,871 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Omada Health during the second quarter worth $15,016,000. Madryn Asset Management LP bought a new position in shares of Omada Health in the 2nd quarter valued at $12,814,410. Finally, Walleye Capital LLC acquired a new stake in shares of Omada Health during the 2nd quarter valued at $11,648,000.
About Omada Health
(
Get Free Report)
Omada Health is a U.S. digital health company that provides virtual care programs for people managing chronic conditions. Its services address areas including diabetes, prediabetes, hypertension, musculoskeletal conditions and weight management. The company combines digital tools, personalized health coaching and, where appropriate, clinical support to help members build health habits and manage their care. Programs may include mobile-app-based guidance and connected devices, such as scales or blood pressure monitors.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.